Abstract: Substituted phenylene di-ethers of the formula; ##STR1## wherein R represents an isopropyl or tertiary butyl group and X represents hydrogen or lower alkyl, and acid addition salts thereof.The compounds are useful anti-arrhythmic agents and also show local anaesthetic activity in mammals. Their methods of preparation are disclosed and also pharmacological preparations containing the same.

Abstract: Naphthyl and tetrahydronaphthyl diethers of the formula ##STR1## wherein A represents a naphthylene group or a 5,6,7,8-tetrahydronaphthylene group having their ether chains attached to the 1 and 2 or 2 and 3 positions or, when A represents a naphthylene group, to the 1 and 8 positions, which aromatic groups may also have substituted therein one to three substituents selected from halogen atoms, lower alkyl, lower alkenyl, benzyl, nitro and lower acyl groups, said substituents being present in the aromatic part in case A represents a 5,6,7,8-tetrahydronaphthylene group and R represents an isopropyl or tertiary butyl group, and acid addition salts thereof.The compounds are useful anti-arrhythmic agents and also show local anaesthetic activity in mammals.

Abstract: New amino-isoquinoline derivatives of the general formula: ##SPC1##Wherein R.sub.1 and R.sub.4 are the same or different and each represents a hydrogen or halogen atom or an alkyl group, R.sub.2 and R.sub.3 are the same or different and each represents a hydrogen or halogen atom or an alkyl or alkoxy group or R.sub.2 and R.sub.3 together represent a methylenedioxy radical, R.sub.5 represents a hydrogen atom or an alkyl or aryl group and R.sub.6 represents a di (lower alkyl) amino group or a nitrogen containing 5- or 6-membered heterocyclic radical linked to the isoquinoline nucleus either through a carbon atom or through the nitrogen atom such as 2-, 3- or 4-pyridyl, or 1-pyrrolidinyl are described. The aforesaid alkyl and alkoxy groups are preferably lower alkyl and lower alkoxy groups respectively. By the terms "lower alkyl" and "lower alkoxy" as used in this specification are meant straight or branched chain alkyl and alkoxy groups respectively having at most 6 carbon atoms.

Abstract: A process is described for the preparation of pyrimidine derivatives having therapeutic properties. They have the general formula: ##SPC1##Wherein A represents an alkylene or alkenylene grouping which together with the carbon atoms of the pyrimidine nucleus to which it is attached forms a homocyclic ring containing five to seven carbon atoms, which homocyclic ring may carry one or more halogen, lower alkyl and/or lower alkoxy substituents and R represents an amino, lower alkylamino or di(lower)alkylamino group, or a nitrogen-, oxygen- or sulphur-containing saturated or unsaturated mononuclear heterocyclic group linked to the pyrimidine ring either through a carbon atom or, when the group contains a nitrogen atom, either through the nitrogen atom or a carbon atom and are prepared by reacting a cycloaliphatic(A)oaminonitrile with a nitrile of the formula R-CN where A and R have the above meanings in the presence of a basic alkali metal-containing compound and then reacting the resultant intermediate with water.